BMY: Sector Tailwinds And Pipeline Milestones Will Shape Next Share Rerating

Analysts have nudged their price targets for Bristol Myers Squibb higher, with moves such as UBS shifting to a Buy rating with a US$65 target from US$46 and Citi lifting its target to US$53 from US$45. This reflects growing confidence tied to sector tailwinds, improving deal activity, and a refreshed view of the company’s valuation and earnings power.

Analyst Commentary

Recent research on Bristol Myers Squibb shows a mix of optimism around sector conditions and deal activity, alongside more cautious views on the company’s execution and relative appeal versus peers.

Bullish Takeaways

• Bullish analysts point to biotech and pharma emerging from what they describe as a cyclical trough, with improving macro conditions, stronger fundamentals, more FDA approvals, positive clinical data, and accelerating M&A activity supporting sentiment toward large drugmakers, including Bristol Myers Squibb.
• The upgrade to a higher price target in the low US$60s signals that some see greater earnings power being recognized in the share price. Sector tailwinds are viewed as helping to re-rate the stock closer to their assessment of fair value.
• Confidence that investor sentiment could improve across large cap pharma over the next couple of years is seen as helpful for Bristol Myers Squibb’s valuation, as the group benefits from broader interest in the sector.

Bearish Takeaways

• More cautious analysts maintain Neutral or Sector Perform stances. They suggest that while the stock reflects some upside from recent targets near the mid US$40s to low US$50s, they do not yet see a clear reason to expect meaningful outperformance versus peers.
• The Sector Perform rating indicates that, in their view, Bristol Myers Squibb’s execution and growth profile are in line with the broader group rather than standing out as a leader. This tempers enthusiasm about re-rating potential.
• Coverage initiations with targets around US$45 point to reservations about how quickly the company can translate sector-level positives into stronger company-specific results that would justify a more premium valuation.
• With other large cap drugmakers receiving more positive ratings, some bearish analysts appear to see better risk reward elsewhere, highlighting relative rather than absolute concerns about Bristol Myers Squibb.

What's in the News

• The U.S. FDA granted priority review to a supplemental biologics license application for Opdivo in combination with AVD in previously untreated Stage III or IV classical Hodgkin lymphoma, with a PDUFA goal date of April 8, 2026, based on the Phase 3 SWOG S1826 study.
• Breyanzi received U.S. FDA approval for adults with relapsed or refractory marginal zone lymphoma after at least two prior lines of systemic therapy, adding another indication for the company’s CD19-directed CAR T cell therapy.
• The European Commission approved Breyanzi for adults with relapsed or refractory mantle cell lymphoma after at least two prior lines of systemic therapy including a BTK inhibitor, extending the therapy’s reach across the EU and EEA.
• Bristol Myers Squibb updated 2025 guidance, setting revenue in a range of US$47.5b to US$48b and an expected EPS range of US$6.40 to US$6.60.
• The company reached a US$239m settlement of claims related to disclosures around Otezla and Zeposia prospects for former Celgene shareholders, subject to court approval. (Reuters)
• Pharma companies, including Bristol Myers Squibb, committed part of more than US$6b toward PD-1/VEGF bispecific antibody rights and trials for potential next generation cancer treatments. (Bloomberg)
• Bristol Myers Squibb was identified as one of the drugmakers participating in a class of PD-1/VEGF combination therapies and was also mentioned among global pharma companies potentially affected by a planned U.S. probe into overseas drug pricing. (Financial Times)
• The company’s quarterly dividend was set at US$0.63 per share, payable February 2, 2026. This corresponds to an annualized rate of US$2.52 per share for the 2026 fiscal year.

Valuation Changes

• Fair Value: risen moderately from US$53.55 to US$56.26 per share, suggesting a higher assessed worth for the stock in updated models.
• Discount Rate: effectively unchanged, moving fractionally from 6.956% to 6.956%, indicating a stable view of risk and required return.
• Revenue Growth: revised slightly lower from a 5.34% decline to a 5.36% decline, pointing to a marginally softer top line outlook in the model.
• Net Profit Margin: trimmed from 21.77% to 21.10%, reflecting a modestly lower expected level of profitability on future sales.
• Future P/E: increased from 15.18x to 16.47x, indicating that the updated assumptions apply a higher valuation multiple to projected earnings.